Physician profile
Amber Marie Blair
NPI 1366782781
$550,697.44
in general payments reported to CMS, 2019-2025
35 companies · $195K in 2025
The $195K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19K · 2022: $31K · 2023: $95K · 2024: $211K · 2025: $195K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $250K · Travel and Lodging: $102K · Consulting Fee: $100K · Food and Beverage: $33K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $15K · Honoraria: $963 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $250,072.92 |
| Travel and Lodging | $102,039.30 |
| Consulting Fee | $99,601.78 |
| Food and Beverage | $33,475.53 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $15,005.00 |
| Honoraria | $962.50 |
| Education | $113.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $141,417.47 | 2021-2025 | Sotyktu, Sprycel |
| Janssen Biotech, INC. | $79,519.82 | 2021-2025 | Tremfya |
| Leo Pharma INC. | $76,501.43 | 2021-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $58,976.88 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $49,247.19 | 2021-2025 | Odomzo, Blu-U, Ilumya |
| Lilly USA, LLC | $35,798.75 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Incyte Corporation | $23,819.54 | 2021-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $19,038.44 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Pfizer INC. | $17,749.86 | 2021-2025 | |
| Ucb, INC. | $12,301.73 | 2021-2025 | Bimzelx |
| Organon LLC | $8,280.31 | 2024-2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $7,778.40 | 2021-2025 | |
| Dermavant Sciences, INC. | $6,911.81 | 2022-2024 | Vtama |
| Genzyme Corporation | $5,862.48 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $2,316.52 | 2025 | Zoryve |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $1,491.09 | 2021 | |
| Mayne Pharma Commercial LLC | $962.50 | 2024 | |
| Abbvie INC. | $611.05 | 2021-2025 | |
| Journey Medical Corporation | $390.08 | 2022-2024 | |
| Verrica Pharmaceuticals INC. | $325.18 | 2024-2025 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $251.19 | 2021-2022 | |
| Amgen INC. | $228.07 | 2021-2023 | Otezla |
| Genentech USA, INC. | $176.32 | 2021 | |
| Biofrontera INC. | $136.60 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Takeda Pharmaceuticals U.S.A., INC. | $112.48 | 2024-2025 | |
| Strata Skin Sciences, INC. | $106.26 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $100.32 | 2021-2025 | Dupixent |
| Almirall LLC | $59.60 | 2021-2023 | Klisyri |
| Vyne Pharmaceuticals INC. | $55.28 | 2021 | |
| Sanofi-Aventis U.S. LLC | $38.28 | 2021 | |
| Janssen Scientific Affairs, LLC | $35.63 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $30.50 | 2024 | |
| Revance Therapeutics, INC. | $28.18 | 2024 | Daxxify |
| Celgene Corporation | $26.00 | 2022 | |
| Masimo Corporation | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Blair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.